insitro is a drug discovery and development company harnessing machine learning and large-scale data to revolutionize the way therapeutics are designed and developed. The company's approach combines in-house generated multi-modal cellular data with extensive human cohort insights to create predictive disease models that identify novel therapeutic targets and patient biomarkers. This integration of advanced computational techniques with experimental biology aims to address inefficiencies in the drug development pipeline, particularly in the areas of neuroscience, oncology, and metabolism. Since its founding in 2018, insitro has established a robust pipeline of both wholly owned and partnered therapeutics and has secured significant funding to drive its mission of transforming patient outcomes through innovative research. Committed to fostering a diverse and inclusive work environment, insitro values collaboration among interdisciplinary teams to accelerate the discovery of impactful medicines.